Last reviewed · How we verify

CD07223 — Competitive Intelligence Brief

CD07223 (CD07223) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CD73 inhibitor. Area: Oncology.

phase 2 CD73 inhibitor CD73 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

CD07223 (CD07223) — Galderma R&D. CD07223 is a small molecule targeting the CD73 enzyme.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
CD07223 TARGET CD07223 Galderma R&D phase 2 CD73 inhibitor CD73

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CD73 inhibitor class)

  1. AstraZeneca · 1 drug in this class
  2. BeiGene · 1 drug in this class
  3. Galderma R&D · 1 drug in this class
  4. Samsung Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CD07223 — Competitive Intelligence Brief. https://druglandscape.com/ci/cd07223. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: